News

Meta-analysis findings suggest a significant association between MASLD and serious bacterial infection risk.

Obesity and advanced fibrosis were independent predictors of impaired health-related quality of life in people with T2D.

This conference talk was titled Acute & Chronic Spontaneous Urticaria: Diagnostic and Therapeutic Strategies and presented a challenging case series to attendees.

Oral vitamin D improves vitamin D status and quality of life in IBS patients but does not significantly reduce symptom severity, a new study suggests.

Test your knowledge of the phase 3 MAESTRO-NASH trial supporting resmetirom (Rezdiffra)’s FDA accelerated approval for MASH with this quiz.

Del Rosso highlights points from his conference talk on benzoyl peroxide (BPO) use among patients with acne and other updates.

With HepQuant DuO and SHUNT tests, investigators could categorize patients with sclerosing cholangitis into low, moderate, and high disease severity subgroups.

Reau explains the importance of second- and third-line treatment in PBC and the potential implications of no longer having OCA after a negative FDA advisory committee meeting.

Arimoclomol, in combination with miglustat, is approved to treat neurological symptoms associated with NPC in adults and children aged ≥2 years.

This segment of her interview featured a conversation about the biggest takeaways and notable case series presented in Culton’s talk at Maui Derm NP+PA Fall.

A new study finds causal links between schizophrenia and MDD on IBS, highlighting the need for integrated care addressing both psychiatric and gastrointestinal symptoms.

Study results suggest C4d is associated with worse renal survival and disease progression to kidney failure in patients with primary IgA nephropathy.

Lp(a) ordering remains low in patients at risk for ASCVD, particularly non-Hispanic Black or Hispanic individuals in socioeconomically disadvantaged neighborhoods.

This interview with Culton featured a discussion of key challenges faced when treating patients with blistering diseases such as pemphigus and bullous pemphigoid.

A study revealed erenumab at 140 mg is effective and safe in achieving remission of headaches caused by non-opioid medication overuse.

In this segment of his interview, Zirwas highlighted the use of JAK inhibitors such as upadacitinib, discussed safety, and touched on topical options for patients with eczema.

Positive topline results from the phase 2a HERALD study of ALG-055009 in MASH highlight the THR-β agonist’s impact on liver fat reduction.

EDG-7500 was well-tolerated in healthy patients in Phase 1 while achieving gradient relief without LVEF reductions in the Phase 2 CIRRUS-HCM trial.

Shapiro spoke in his Maui Derm NP+PA Fall conference interview about differentiating between types of alopecia areata and about the potential use of JAK inhibitors.

The model Revised REACH-B outperforms an earlier model by incorporating predictors of predictors of age, sex, platelet count, ALT levels, and positive hepatitis B antigen result.

The FDA declined to approve the NDA for tradipitant for the treatment of symptoms of gastroparesis, suggesting that Vanda conduct additional studies.

High-risk SAFE scores were linked to increased mortality, especially in participants with alcohol-associated liver disease, as this group demonstrated the worst survival.

Ferric carboxymaltose achieved superior outcomes to an oral iron tablet for the treatment of anemia in pregnant women.

Zirwas described several highlights from his presentation on updates in managing atopic dermatitis, describing examples such as lebrikizumab and nemolizumab.

Inpatients receiving brief cognitive behavioral therapy had a 60% reduced likelihood of suicide attempts and a 71% reduced rate of psychiatric readmissions post-discharge.

The new guidance reviews existing tools for weight management and provides recommendations for their use in clinical practice in patients with obesity and kidney disease.

Amanda Wilson, PhD, details how her team is developing risk assessment models to evaluate viral infection intervention in schools.

In her Maui Derm NP+PA Fall interview, Harper highlighted treatment approaches and unmet needs of patients with acne.